NCT00389480 Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies Status COMPLETED Phase PHASE1
NCT00389077 Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas Status COMPLETED Phase PHASE2
NCT00382733 Oral Topotecan to Treat Recurrent or Persistent Solid Tumors Status COMPLETED Phase PHASE1/PHASE2
NCT00373490 A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) Status COMPLETED Phase PHASE1
NCT00372437 A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine Status COMPLETED Phase PHASE1/PHASE2
NCT00364676 Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease Status COMPLETED Phase PHASE1
NCT00363610 A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma Status TERMINATED Phase PHASE1
NCT00358397 One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy Status TERMINATED Phase PHASE1
NCT00339144 Study of Dasatinib (BMS-354825) in Patients With Solid Tumors Status COMPLETED Phase PHASE1
NCT00338026 A Phase I Study of ECO-4601 in Patients With Advanced Cancer Status COMPLETED Phase PHASE1
NCT00323934 Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Status COMPLETED Phase PHASE1
NCT00313456 A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel Status TERMINATED Phase PHASE1
NCT00309023 Study of BMS-663513 in Patients With Advanced Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT00299728 NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors Status COMPLETED Phase PHASE1
NCT00298779 Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma. Status COMPLETED Phase PHASE1
NCT00298675 Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors Status COMPLETED Phase PHASE1